Abstract 1795P
Background
Serplulimab plus chemotherapy has been well-established as a standard first-line treatment for extensive-stage small-cell lung cancer (SCLC) via the ASTRUM-005 trial. However, its role as consolidation monotherapy in limited-stage SCLC (LS-SCLC) remains uncertain.
Methods
This multicenter, phase Ⅱ trial (ASTRUM-LC01) has been registered at ClinicalTrials.gov (NCT05443646). We enrolled LS-SCLC patients who did not progress after 4 cycles of standard chemotherapy, concurrent hypofractionated radiotherapy (45Gy/3Gy/15F), and prophylactic cranial irradiation (25Gy/2.5Gy/10F). These patients then received consolidation serplulimab 300mg every 3 weeks for up to 1 year until progression or unacceptable toxicity. This preliminary analysis aimed to evaluate the objective response rate (ORR), depth of response (DpR), disease control rate (DCR), survival outcomes, and safety profile.
Results
Between May 2022 and August 2023, 55 patients were enrolled, 69.1% being male and 81.8% at stage Ⅲ. The median age was 60 years. The date of data cut-off was April 7, 2024. The median follow-up duration since initiating serplulimab was 9.8 months, and 31 (56.4%) patients remained on treatment. The median cycles of consolidation therapy were 8, and 9 (16.4%) patients had completed the prescribed treatment. The ORR and DCR following serplulimab treatment were both 96.4% (95% CI 87.5-99.6), and 90.9% of patients achieved a DpR exceeding 50%. The median PFS was not reached, with a 1-year PFS rate of 71.8% (95% CI 60.1-85.8) from the first dose of consolidation therapy. Treatment-related adverse events (TRAEs) were reported in 72.7% of patients, with 14.6% experiencing grade 3-4 TRAEs, and pneumonitis (5.45%) being the most common. Four patients discontinued the study due to TRAEs, and no treatment-related death event was reported.
Conclusions
These results highlight the potential survival benefit and manageable safety of consolidation serplulimab therapy in LS-SCLC.
Clinical trial identification
NCT05443646.
Editorial acknowledgement
Legal entity responsible for the study
Y. Wu.
Funding
Shanghai Henlius Biotech, Inc. (2696.HK).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
84P - Advancing precision oncology: Integrating immune landscape and genomics for tailored therapy in metastatic cancer patients
Presenter: Eurydice Angeli
Session: Poster session 07
85P - True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients
Presenter: Manoj Dongare
Session: Poster session 07
Resources:
Abstract
86P - Making the precision oncology landscape of Europe and the Republic of Ireland programmatically accessible
Presenter: Brendan Reardon
Session: Poster session 07
87P - Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making
Presenter: Fatima Usman
Session: Poster session 07
88P - Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry
Presenter: Christophe Le Tourneau
Session: Poster session 07
89P - Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: A sub-project of the IMPRESS-Norway trial
Presenter: Ingrid Dyvik
Session: Poster session 07
90P - Clonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies
Presenter: Pasquale Rescigno
Session: Poster session 07
91P - Ultra-sensitive ctDNA NGS assay enhances genomic profiling for advanced HR-positive, HER2-negative breast cancer on endocrine therapy
Presenter: Hao Liao
Session: Poster session 07
92P - Transformative diagnostics in urothelial carcinoma: Utilizing targeted NGS and LP-WGS for non-invasive detection and personalized medicine
Presenter: Huan Zhao
Session: Poster session 07
93P - UriMee: A novel non-invasive test for diagnosis of urothelial carcinoma by detection of methylation markers in urinary sediment DNA
Presenter: Ming cao
Session: Poster session 07